Skip to main content

Resolution Bioscience, Mirati Therapeutics Sign Companion Diagnostic Agreement

NEW YORK – Resolution Bioscience said on Monday that it has signed a companion diagnostic agreement with San Diego-based Mirati Therapeutics.

As part of the collaboration, the firms will use Kirkland, Washington-based Resolution's ctDx liquid biopsy technology to help find non-small cell lung cancer (NSCLC) patients who may benefit from Mirati's investigational KRAS G12C inhibitor therapy.

Resolution's ctDx Lung Assay, which is covered by Medicare and private payors, applies next-generation sequencing to look for actionable mutations in cell-free DNA in a NSCLC patient's blood sample.

Mirati's adagrasib (MRTX849) is an orally available small molecule that selectively inhibits the G12C substitution mutation. The partners will use the ctDx Lung Assay to spot NSCLC patients whose cancer are driven by the G12C variant.

Financial details of the agreement were not disclosed.

"We are excited to join forces with Mirati to address this large unmet medical need and to further drive adoption of our innovative liquid biopsy diagnostic tests," Mark Li, CEO of Resolution Bioscience, said in a statement. "Our mission is to provide critical [and] actionable information to improve care and clinical care outcomes for cancer patients worldwide."